<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054314</url>
  </required_header>
  <id_info>
    <org_study_id>DS 02-04</org_study_id>
    <secondary_id>RPCI-DS-0204</secondary_id>
    <secondary_id>BAYER-10653</secondary_id>
    <nct_id>NCT00054314</nct_id>
  </id_info>
  <brief_title>BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who&#xD;
      have non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the overall response rate, including partial and complete response, in&#xD;
           patients with taxane-resistant non-small cell lung cancer treated with BAY 59-8862.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine duration of response and time to progression in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the quantitative and qualitative toxic effects of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive BAY 59-8862 IV over 1 hour on day 1. Courses repeat every 3 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients with responding disease&#xD;
      receive 2-4 additional courses beyond maximal response.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-84 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ortataxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  A CNS lesion cannot be the sole target lesion&#xD;
&#xD;
          -  Must be taxane-resistant as defined by the following criteria:&#xD;
&#xD;
               -  At least 1 prior course (3 weeks of continuous therapy) of a taxane&#xD;
&#xD;
               -  Progressive disease developed either during or within 6 months after therapy&#xD;
&#xD;
          -  No metastatic brain or meningeal tumors unless the following criteria apply:&#xD;
&#xD;
               -  More than 6 months since definitive therapy&#xD;
&#xD;
               -  Negative imaging study within the past 4 weeks&#xD;
&#xD;
               -  Clinically stable with respect to the tumor&#xD;
&#xD;
               -  No concurrent acute steroid therapy or taper&#xD;
&#xD;
                    -  Chronic steroids allowed provided dose is stable for 1 month before and&#xD;
                       after screening radiography&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST no greater than 2.5 times ULN (5 times ULN if liver involvement)&#xD;
&#xD;
          -  No chronic hepatitis B or C&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No serious cardiac arrhythmias&#xD;
&#xD;
          -  No active coronary disease or ischemia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active clinically serious infection&#xD;
&#xD;
          -  No history of seizure disorder&#xD;
&#xD;
               -  History of seizures related to brain metastasis allowed if seizure free for the&#xD;
                  past 2 months&#xD;
&#xD;
          -  No prior hypersensitivity to taxane compounds that was unmanageable with premedication&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy greater than grade 1&#xD;
&#xD;
          -  No other malignancy within the past 3 years except carcinoma in situ of the cervix,&#xD;
             adequately treated basal cell carcinoma, or superficial bladder tumors (Ta, Tis, and&#xD;
             T1)&#xD;
&#xD;
          -  No substance abuse&#xD;
&#xD;
          -  No medical, psychological, or social condition that would preclude study participation&#xD;
             or evaluation&#xD;
&#xD;
          -  No condition that is unstable or would jeopardize patient safety and study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 3 weeks since prior anticancer immunotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior biologic response modifiers (e.g., filgrastim [G-CSF])&#xD;
&#xD;
          -  More than 4 months since prior bone marrow transplantation or stem cell rescue&#xD;
&#xD;
          -  No concurrent anticancer immunotherapy&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed if dose is stable for the past 2 months&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior anticancer chemotherapy (6 weeks for mitomycin or&#xD;
             nitrosoureas)&#xD;
&#xD;
          -  No more than 2 prior anticancer chemotherapy regimens (adjuvant therapy is not&#xD;
             included unless cancer recurred during or within 6 months after completion of adjuvant&#xD;
             therapy)&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent non-palliative radiotherapy&#xD;
&#xD;
               -  Palliative radiotherapy allowed provided that all of the following criteria are&#xD;
                  met:&#xD;
&#xD;
                    -  No progressive disease&#xD;
&#xD;
                    -  No more than 10% of the bone marrow is irradiated&#xD;
&#xD;
                    -  Radiation field does not encompass a target lesion&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior surgery&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drug therapy&#xD;
&#xD;
          -  No concurrent non-conventional therapies (e.g., herbs or acupuncture) or&#xD;
             vitamin/mineral supplements that would interfere with study endpoints&#xD;
&#xD;
          -  No other concurrent investigational drug therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nithya Ramnath, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>IDN 5109</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

